BACKGROUND: B-cell survival is regulated through interactions of B-cell-activating factor and a proliferation-inducing ligand with their receptors transmembrane activator and CAML interactor (TACI) and B-cell maturation antigen (BCMA). We evaluated the diagnostic potential of soluble TACI (sTACI) and soluble BCMA (sBCMA) in CSF and serum as biomarkers in primary CNS lymphoma (PCNSL). METHODS: CSF (n = 176) and serum samples (n = 105) from patients with clinically or radiologically suspected PCNSL as well as from control patients were collected prospectively. Levels of sTACI and sBCMA were analyzed by enzyme-linked immunosorbent assay. Additionally, in patients with PCNSL, CSF was analyzed during disease course (time of diagnosis, n = 26; relapse, n = 10; remission, n = 14), and in 2 patients long-term longitudinal analysis was performed. RESULTS: Soluble TACI and sBCMA are significantly increased in patients with PCNSL (sTACI, median: 445 pg/mL; sBCMA, median: 760 pg/mL) compared with control patients (sTACI, median: 0 pg/mL; sBCMA, median: 290 pg/mL). At a cutoff value of 68.4 pg/mL, sTACI shows high sensitivity (87.9%) and specificity (88.3%) for the diagnosis of active PCNSL. Soluble BCMA is less sensitive (72.7%) and specific (71.8%) (cutoff: 460 pg/mL). When both markers are combined, specificity increases, however, at the cost of a lower sensitivity. In serum, both sTACI and sBCMA are not increased in PCNSL patients. Both soluble receptors correlate with clinical course and therapy response. CONCLUSIONS: Our results suggest that sTACI and sBCMA in the CSF are promising new biomarkers for diagnosis and therapy monitoring in PCNSL. However, our findings need to be validated in an independent cohort.
BACKGROUND: B-cell survival is regulated through interactions of B-cell-activating factor and a proliferation-inducing ligand with their receptors transmembrane activator and CAML interactor (TACI) and B-cell maturation antigen (BCMA). We evaluated the diagnostic potential of soluble TACI (sTACI) and soluble BCMA (sBCMA) in CSF and serum as biomarkers in primary CNS lymphoma (PCNSL). METHODS: CSF (n = 176) and serum samples (n = 105) from patients with clinically or radiologically suspected PCNSL as well as from control patients were collected prospectively. Levels of sTACI and sBCMA were analyzed by enzyme-linked immunosorbent assay. Additionally, in patients with PCNSL, CSF was analyzed during disease course (time of diagnosis, n = 26; relapse, n = 10; remission, n = 14), and in 2 patients long-term longitudinal analysis was performed. RESULTS: Soluble TACI and sBCMA are significantly increased in patients with PCNSL (sTACI, median: 445 pg/mL; sBCMA, median: 760 pg/mL) compared with control patients (sTACI, median: 0 pg/mL; sBCMA, median: 290 pg/mL). At a cutoff value of 68.4 pg/mL, sTACI shows high sensitivity (87.9%) and specificity (88.3%) for the diagnosis of active PCNSL. Soluble BCMA is less sensitive (72.7%) and specific (71.8%) (cutoff: 460 pg/mL). When both markers are combined, specificity increases, however, at the cost of a lower sensitivity. In serum, both sTACI and sBCMA are not increased in PCNSL patients. Both soluble receptors correlate with clinical course and therapy response. CONCLUSIONS: Our results suggest that sTACI and sBCMA in the CSF are promising new biomarkers for diagnosis and therapy monitoring in PCNSL. However, our findings need to be validated in an independent cohort.
Authors: Lauren E Abrey; Leah Ben-Porat; Katherine S Panageas; Joachim Yahalom; Brian Berkey; Walter Curran; Christopher Schultz; Steven Leibel; Diana Nelson; Minesh Mehta; Lisa M DeAngelis Journal: J Clin Oncol Date: 2006-11-20 Impact factor: 44.544
Authors: M J Kersten; L M Evers; P L Dellemijn; H van den Berg; P Portegies; R Q Hintzen; R A van Lier; A E von dem Borne; R H van Oers Journal: Blood Date: 1996-03-01 Impact factor: 22.113
Authors: Isabel Legaz; Manuel Muro; Rafael Alfaro; Santiago Llorente; Pedro Martinez; Víctor Jimenez-Coll; Helios Martínez-Banaclocha; José Antonio Galián; Carmen Botella; María Rosa Moya-Quiles; Jesús de la Peña-Moral; Alfredo Minguela Journal: Arch Immunol Ther Exp (Warsz) Date: 2022-09-22 Impact factor: 3.831
Authors: Anouk van Westrhenen; Lisanne C A Smidt; Tatjana Seute; Stefan Nierkens; Abraham C J Stork; Monique C Minnema; Tom J Snijders Journal: Br J Haematol Date: 2018-05-29 Impact factor: 6.998
Authors: Matthias Mulazzani; Marion Huber; Sabine Borchard; Sigrid Langer; Barbara Angele; Elisabeth Schuh; Edgar Meinl; Martin Dreyling; Tobias Birnbaum; Andreas Straube; Uwe Koedel; Louisa von Baumgarten Journal: J Hematol Oncol Date: 2019-10-15 Impact factor: 17.388
Authors: Giancarlo Comi; Amit Bar-Or; Hans Lassmann; Antonio Uccelli; Hans-Peter Hartung; Xavier Montalban; Per Solberg Sørensen; Reinhard Hohlfeld; Stephen L Hauser Journal: Ann Neurol Date: 2020-11-04 Impact factor: 10.422
Authors: Philip A Egan; Patrick T Elder; W Ian Deighan; Sheila J M O'Connor; H Denis Alexander Journal: Haematologica Date: 2020-05-15 Impact factor: 9.941